CL2021001968A1 - Sales de sulcardina - Google Patents

Sales de sulcardina

Info

Publication number
CL2021001968A1
CL2021001968A1 CL2021001968A CL2021001968A CL2021001968A1 CL 2021001968 A1 CL2021001968 A1 CL 2021001968A1 CL 2021001968 A CL2021001968 A CL 2021001968A CL 2021001968 A CL2021001968 A CL 2021001968A CL 2021001968 A1 CL2021001968 A1 CL 2021001968A1
Authority
CL
Chile
Prior art keywords
salts
sulcardine
sulcardine salts
methods
sulfuric acid
Prior art date
Application number
CL2021001968A
Other languages
English (en)
Spanish (es)
Inventor
Suzanne J Romano
Hayley Ann Reece
Joseph Edward Gordon Benson
Sarah Collins
Gary T Elliott
Mireille Gillings
Robert Goodenow
Curtis Tyree
Original Assignee
Huya Bioscience Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huya Bioscience Int Llc filed Critical Huya Bioscience Int Llc
Publication of CL2021001968A1 publication Critical patent/CL2021001968A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Chemistry (AREA)
CL2021001968A 2019-01-29 2021-07-27 Sales de sulcardina CL2021001968A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962798467P 2019-01-29 2019-01-29
US202062959687P 2020-01-10 2020-01-10

Publications (1)

Publication Number Publication Date
CL2021001968A1 true CL2021001968A1 (es) 2022-01-28

Family

ID=69724142

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001968A CL2021001968A1 (es) 2019-01-29 2021-07-27 Sales de sulcardina

Country Status (16)

Country Link
US (4) US11426382B2 (cg-RX-API-DMAC10.html)
EP (1) EP3917921A1 (cg-RX-API-DMAC10.html)
JP (3) JP2022518906A (cg-RX-API-DMAC10.html)
KR (2) KR102405199B1 (cg-RX-API-DMAC10.html)
CN (2) CN112638903B (cg-RX-API-DMAC10.html)
AU (1) AU2020216925B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021014640A8 (cg-RX-API-DMAC10.html)
CA (1) CA3128152A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021001968A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021011042A2 (cg-RX-API-DMAC10.html)
IL (1) IL285184B2 (cg-RX-API-DMAC10.html)
MX (2) MX2021009033A (cg-RX-API-DMAC10.html)
PH (1) PH12021551818A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202108160YA (cg-RX-API-DMAC10.html)
WO (1) WO2020159959A1 (cg-RX-API-DMAC10.html)
ZA (2) ZA202105344B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123824A1 (en) 2018-12-13 2020-06-18 Huya Bioscience International, Llc Sulcardine administration for treatment of acute atrial fibrillation
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염
US11813245B2 (en) * 2020-06-12 2023-11-14 Huyabio International, Llc Sulcardine administration for treatment of acute atrial fibrillation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1299813C (zh) 2004-12-28 2007-02-14 华南理工大学 自动撕膜落料及多样性搅拌的机构和控制装置
CN1939298A (zh) * 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
US8541464B2 (en) 2009-11-17 2013-09-24 HUYA Biosciences International LLC Treatment of atrial fibrillation
WO2011062903A2 (en) * 2009-11-17 2011-05-26 Elliott Gary T Slow infusion of sulcardine and its salts
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
AU2018212273B2 (en) 2017-01-26 2023-12-21 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
US10370381B2 (en) * 2017-02-24 2019-08-06 Gilead Sciences, Inc. Inhibitors of bruton'S tyrosine kinase
WO2020123824A1 (en) 2018-12-13 2020-06-18 Huya Bioscience International, Llc Sulcardine administration for treatment of acute atrial fibrillation
KR102405199B1 (ko) * 2019-01-29 2022-06-02 후야 바이오사이언스 인터내셔널 엘엘씨 설카딘 염

Also Published As

Publication number Publication date
AU2020216925B2 (en) 2022-09-15
ZA202107474B (en) 2022-06-29
US20250144072A9 (en) 2025-05-08
KR102405199B1 (ko) 2022-06-02
CN115385871A (zh) 2022-11-25
US20200316024A1 (en) 2020-10-08
JP2025165933A (ja) 2025-11-05
IL285184A (en) 2021-09-30
IL285184B2 (en) 2023-12-01
CO2021011042A2 (es) 2022-01-17
US20260232630A1 (en) 2026-08-13
MX2023014776A (es) 2024-01-15
JP2022518906A (ja) 2022-03-17
US20220356319A1 (en) 2022-11-10
CN112638903B (zh) 2022-08-26
CA3128152A1 (en) 2020-08-06
EP3917921A1 (en) 2021-12-08
KR102697726B1 (ko) 2024-08-21
BR112021014640A8 (pt) 2022-12-20
PH12021551818A1 (en) 2022-03-28
AU2020216925A1 (en) 2021-09-02
US11426382B2 (en) 2022-08-30
US12678422B2 (en) 2026-07-14
KR20210130157A (ko) 2021-10-29
US11020374B2 (en) 2021-06-01
CN112638903A (zh) 2021-04-09
KR20220079688A (ko) 2022-06-13
BR112021014640A2 (pt) 2021-09-21
JP2024039020A (ja) 2024-03-21
IL285184B1 (en) 2023-08-01
ZA202105344B (en) 2023-01-25
US20210038568A1 (en) 2021-02-11
WO2020159959A1 (en) 2020-08-06
MX2021009033A (es) 2021-10-13
SG11202108160YA (en) 2021-08-30

Similar Documents

Publication Publication Date Title
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
CY1126110T1 (el) Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6
MX2021009276A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2.
MX2020013726A (es) Compuestos antagonistas de pcsk9.
MX383856B (es) Compuestos y composiciones para inhibir la actividad de shp2.
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
MX376584B (es) Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
UY37997A (es) Agentes antivirales contra la hepatitis b
CO2021011042A2 (es) Sales de sulcardina
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
MX391620B (es) Formulaciones del inhibidor del antígeno-1 asociado a la función de linfocitos (lfa-1).
BR112017000584A2 (pt) inibidores da aldosterona sintase
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
BR112022005736A2 (pt) Compostos de azaindol carboxamida para o tratamento de infecções micobacterianas